Skip to content
Cart

Your Cart

×

You have 0 items in your cart.

Register Sign in Wishlist

Drug Wars
How Big Pharma Raises Prices and Keeps Generics off the Market

$29.99 (G)

  • Authors:
  • Robin Feldman, University of California Hastings College of Law
  • Evan Frondorf, University of California Hastings College of Law
  • Date Published: June 2017
  • availability: In stock
  • format: Hardback
  • isbn: 9781107168480

$ 29.99 (G)
Hardback

Add to cart Add to wishlist

Other available formats:
eBook


Looking for an examination copy?

If you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact collegesales@cambridge.org providing details of the course you are teaching.

Description
Product filter button
Description
Contents
Resources
Courses
About the Authors
  • While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.

    • Explains important trends in the pharmaceutical industry while remaining reader-friendly
    • Covers public pricing scandals involving Martin Shkreli and other characters, providing a 'behind-the-scenes' look at high pharmaceutical prices
    • Offers an organized history of generic pharmaceutical delay, with strategies sorted in easy-to-follow categories
    Read more

    Reviews & endorsements

    'An important book and a compelling read. The authors show how pharmaceutical companies have twisted a law designed to protect invention into a regulatory nightmare that only protects profits.' Mark A. Lemley, William H. Neukom Professor, Stanford Law School, California

    'A fascinating and incisive study of the inner world of the pharmaceutical industry. A must read for anyone interested in the relationship between drug pricing, regulation, and its impact on public health.' Sonia K. Katyal, Chancellor's Professor of Law, University of California, Berkeley

    See more reviews

    Customer reviews

    Not yet reviewed

    Be the first to review

    Review was not posted due to profanity

    ×

    , create a review

    (If you're not , sign out)

    Please enter the right captcha value
    Please enter a star rating.
    Your review must be a minimum of 12 words.

    How do you rate this item?

    ×

    Product details

    • Date Published: June 2017
    • format: Hardback
    • isbn: 9781107168480
    • length: 160 pages
    • dimensions: 235 x 158 x 14 mm
    • weight: 0.38kg
    • availability: In stock
  • Table of Contents

    Introduction: big scandals, higher prices
    1. The winding road to generic entry
    2. 'Generation 1.0': the rise and fall of traditional pay-for-delay
    3. 'Generation 2.0': complicating pay-for-delay
    4. 'Generation 3.0': new tactics for active obstruction of generics
    5. 'Generation 3.0' continued: obstruction of regulatory pathways
    6. Empirical evidence of a citizen's pathway gone astray
    Conclusion: a call for systematic reform.

  • Authors

    Robin Feldman, University of California Hastings College of Law
    Robin Feldman is an award-winning teacher and scholar who has published more than forty articles and books. Feldman has been cited by the White House, members of Congress, and numerous federal agencies, and she has testified before committees of the US House and Senate, as well as the California legislature. In 2016, Feldman was named as one of the Women Leaders in Law and Technology, the only academic to receive the honor.

    Evan Frondorf, University of California Hastings College of Law
    Evan Frondorf's legal work with Robin Feldman has been published in journals at Harvard University, Massachusetts and Stanford University, California, including papers on patent demands and generic pharmaceuticals. He studied economics at Yale University, Connecticut and graduated Phi Beta Kappa and magna cum laude, and he was also named a Rhodes Scholar finalist in 2015. He is the current sportswriter for the Yale Alumni Magazine. At Yale, he was heavily involved in sports broadcasting and served as a deputy sports editor at the Yale Daily News.

Sign In

Please sign in to access your account

Cancel

Not already registered? Create an account now. ×

Sorry, this resource is locked

Please register or sign in to request access. If you are having problems accessing these resources please email lecturers@cambridge.org

Register Sign in
Please note that this file is password protected. You will be asked to input your password on the next screen.

» Proceed

You are now leaving the Cambridge University Press website. Your eBook purchase and download will be completed by our partner www.ebooks.com. Please see the permission section of the www.ebooks.com catalogue page for details of the print & copy limits on our eBooks.

Continue ×

Continue ×

Continue ×

Find content that relates to you

Are you sure you want to delete your account?

This cannot be undone.

Cancel

Thank you for your feedback which will help us improve our service.

If you requested a response, we will make sure to get back to you shortly.

×
Please fill in the required fields in your feedback submission.
×